Forbes October 10, 2024
Artificial intelligence (AI) has been revolutionizing much of early drug discovery, yet human clinical trials remain a bottleneck. Now some applications of the new technologies are bringing efficiencies to clinical research.
Sophisticated modeling and simulations suggests that AI can play a major role in improving the success rates of novel drugs entering human studies. The pharmaceutical industry has long struggled with efficiency rates. According to the the Congressional Budget Office (CBO), only 14% of drugs that enter clinical trials are ultimately approved by the FDA. The development process is complex and can take many years, with many drugs failing at various stages. Estimates are that the cost of developing one drug can be over $2 Billion.
The goal of modeling...
Today's Sponsors
Today's Sponsor